LLY compared with RLYB: revenue, margins and what each company keeps, and the suppliers and customers both name

LLYELI Lilly & Co

Mkt capRevenueRevenue

RLYBRallybio Corp

Mkt capRevenueRevenue

Compare

LLYELI Lilly & Co

RLYBRallybio Corp

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

LLYELI Lilly & Co

1,407.25· pre 1,448.38

Mkt cap$1.3TRevenue$24.4BQ3 FY26Revenue$65.2BFY25

RLYBRallybio Corp

15.51· pre 15.86

Pre-marketNov 4 '26

Mkt cap$85.4MRevenue$212,000Q1 FY26Revenue$858,000FY25

Compare

Pre-marketNov 4 '26

LLYELI Lilly & Co

RLYBRallybio Corp

1,407.25pre 1,448.38

Price

15.51pre 15.86

$1.3T

Mkt cap

$85.4M

Q3 FY26$24.4B

Revenue

$212,000Q1 FY26

FY25$65.2B

Revenue

$858,000FY25

LLY1,407.25vsRLYB15.51Pre-marketNov 4 '26

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

Supply-chain overlap

Revenue flow

RLYB: latest quarter is a loss; flow not drawable.Method ›

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only LLY 29

MCKMcKessoncustomer

CAHCardinal Healthcustomer

VEEVVeeva Systemssupplier

UTHRUnited Therapeuticscustomer

25 more · LLY chain ›

Shared 0

No shared counterparties.

Only RLYB 9

JNJJohnson & Johnson, through its wholly-owned subsidiary, Momenta Pharmaceuticals, Inc. ("J&J")customer

RXRXRecursioncustomer

SNYKymab Limited (Sanofi)supplier

ABCLAbCellera Biologics

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

supplier

5 more · RLYB chain ›

Price

rebased to 0%

LLY, solidRLYB, dashed